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Multiple myeloma (MM) remains as an incurable disease and, although allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) is a potentially curative approach, most patients ultimately relapse, and their treatment
remains challenging. Because allo-HSCT can modify not only the biology of the disease, but also the immune sys-
tem and the microenvironment, it can potentially enhance the response to rescue therapies. Information on the
efficacy and safety of novel drugs in patients relapsing after allo-HSCT is lacking, however. The objectives of this
study were to evaluate the efficacy and toxicity of rescue therapies in patients with MM who relapsed after allo-
HSCT, as well as to compare their efficacy before and after allo-HSCT. This retrospective multicenter study
included 126 consecutive patients with MM who underwent allo-HSCT between 2000 and 2013 at 8 Spanish cen-
ters. All patients engrafted. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 47%, and non-
relapse mortality within the first 100 days post-transplantation was 13%. After a median follow-up of 92 months,
overall survival (OS) was 51% at 2 years and 43% at 5 years. The median progression-free survival after allo-HSCT
was 7 months, whereas the median OS after relapse was 33 months. Patients relapsing in the first 6 months after
transplantation had a dismal prognosis compared with those who relapsed later (median OS, 11 months versus
120 months; P < .001). The absence of chronic GVHD was associated with reduced OS after relapse (hazard ratio,
3.44; P < .001). Most patients responded to rescue therapies, including proteasome inhibitors (PIs; 62%) and
immunomodulatory drugs (IMiDs; 77%), with a good toxicity profile. An in-depth evaluation, including the type
and intensity of PI- and IMiD-based combinations used before and after allo-HSCT, showed that the overall
response rate and duration of response after allo-HSCT were similar to those seen in the pretransplantation
period. Patients with MM who relapse after allo-HSCT should be considered candidates for therapy with new
drugs, which can achieve similar response rates with similar durability as seen in the pretransplantation period.
This pattern does not follow the usual course of the disease outside the transplantation setting, where response
rates and time to progression decreases with each consecutive line of treatment.
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Multiple myeloma (MM) is a neoplastic plasma cell disorder
characterized by clonal proliferation of malignant plasma cells
in the bone marrow and the presence of a monoclonal protein
in the blood and/or urine, resulting in myeloma-defining
events. The outcomes of patients with MM have improved sig-
nificantly due to the introduction of novel agents in both the
relapse and upfront settings; however, the disease remains
incurable for most patients. The role of allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT) in treating MM
remains challenging, because although it is a potentially cura-
tive approach [14], the associated high toxicity and relapse
rate are important concerns. In this regard, the International
MyelomaWorking Group together with the Blood and Marrow
Transplant Clinical Trials Network, the American Society of
Blood and Marrow Transplantation, and the European Society
of Blood and Marrow Transplantation (EBMT) have agreed that
allo-HSCT should be considered an appropriate therapy for all
eligible patients with early relapse (occurring within
24 months) after primary therapy that included autologous
stem cell transplantation (ASCT) and/or high-risk features,
while acknowledging that prospective randomized trials are
needed to define the role of allo-HSCT in patients who relapse
after primary therapy for MM [5].
Allo-HSCT offers a graft-versus-myeloma effect that may be
agnostic to cytogenetic risk. The unacceptably high morbidity
and nonrelapse mortality (NRM), related at least in part to the
use of myeloablative conditioning regimens [69], have
resulted in a shift toward reduced-intensity conditioning (allo-
RIC) regimens [1016]. Despite this, the decision to proceed to
allo-HSCT is increasingly challenging with the advent of new
therapies. However, although the role of allo-HSCT is a subject
of intense debate, survey studies by the EBMT have shown an
increasing number of patients undergoing allo-HSCT for MM
[17], and in fact, the use of novel drugs does not appear to
have impacted the rate of transplantation [18].
Despite the high response rate and the reduced NRM
observed in the years after the advent of allo-RIC regimens,
most patients ultimately relapse. Thus, relapse and progression
are the main causes of treatment failure. Treatment of patients
who relapse after allo-HSCT remains a challenge. Until
recently, these patients have not been considered candidates
for treatment with experimental drugs, based mainly on con-
cerns regarding the toxicity profile of these drugs in the trans-
plantation setting. Moreover, most of the recent trials that
have led to the approval of new drugs excluded allo-HSCT
recipients, and thus these drugs’ efficacy has not been appro-
priately evaluated in this setting. Several small studies have
been reported describing the efficacy of proteasome inhibitors
(PIs) or immunomodulatory drugs (IMiDs) with or without
concomitant donor lymphocyte infusion (DLI) as salvage ther-
apy after allo-HSCT [1923], but none of these has compared
the efficacy achieved after allo-HSCT with that obtained pre-
transplantation with similar combinations. It is well known
that the outcomes of patients with MM follows a pattern in
which the response rate decreases and the median duration of
response decreases after each consecutive line of therapy, a
process that ultimately leads to treatment failure and death
[24]. Whether or not this concept applies to relapse after allo-
HSCT has not been evaluated, and considering the changes to
the immune system and microenvironment induced by the
allograft, this scenario might represent a good opportunity to
evaluate the efficacy of novel agents before and after trans-
plantation.The present study evaluated the outcomes of a series of 126
patients with MM who underwent allo-HSCT. After a median
follow-up of 92 months, overall survival (OS) was 51% at
2 years and 43% at 5 years, with 10% of patients alive at longer
than 10 years beyond transplantation. The median OS after
relapse was 33 months. Most patients responded to rescue
therapy including PIs (62%) and IMiDs (77%) with good tolera-
bility. Moreover, this is the first study to compare the efficacy
and toxicity of novel drug/novel combinations before and after
allo-HSCT, and we show that they can be safely used and that
the response rate and duration of response are similar to those
observed in the pretransplantation setting, indicating that
allo-HSCT can potentially sensitize myelomatous plasma cells,
modifying the usual course of MM.METHODS
Patients
We report a retrospective multicenter analysis of 126 consecutive
patients with MM who underwent allo-HSCT between January 2000 and
December 2013 at 8 Spanish centers. The institutional Ethics Committees of
all participating centers approved the study, and all patients provided written
informed consent before entering the study in accordance with the Declara-
tion of Helsinki. All but 2 procedures were done as routine clinical practice
outside of an investigational clinical trial.Disease Response and Definitions
Response to treatment and progression were determined according to
the criteria formulated by the International Myeloma Working Group [25].
Complete response (CR) was defined as negative immunofixation in serum
and urine and<5% plasma cells in bone marrow aspirate, including the disap-
pearance of any soft tissue plasmacytoma. Progression-free survival (PFS) was
defined as the time from allo-HSCT to the date of progression or death from
any cause or last follow-up. Patients alive without progression at their last
follow-up were censored. OS was defined as the time from allo-HSCT to the
date of death or last follow-up. Patients alive at their last follow-up were cen-
sored. OS after relapse was defined as the time from relapse after allo-HSCT
to the date of death or last follow-up. NRMwas defined as death without pre-
vious occurrence of relapse or progression. Relapse incidence (RI) was calcu-
lated from the date of allo-HSCT to the date of relapse or progression. NRM
and RI were considered competing events.
Deaths due to infection (bacterial, fungal, or viral) in the context of active
graft-versus-host disease (GVHD) were considered related to GVHD. Acute
GVHD (aGVHD) was defined as grade II-IV according to the Seattle criteria
[26]. Chronic GVHD (cGHVD) was defined as mild, moderate, or severe
according to National Institutes of Health 2005 criteria [27]. Patients who had
evidence of engraftment were evaluable for aGVHD, whereas patients who
engrafted and survived longer than 100 days after allo-HSCT were evaluable
for cGVHD, with death or progression/relapse without cGVHD as competing
events.Statistical Analysis
The co-primary endpoints of this study were (1) to evaluate the efficacy
and safety of rescue regimens based on PIs and IMiDs in patients with MM
who relapsed after allo-HSCT and (2) to compare the efficacy after allo-HSCT
with that observed before allo-HSCT for the same patients treated with simi-
lar combinations before and after transplantation. Secondary endpoints
included the efficacy of allo-HSCT in terms of response and RI, PFS, and OS.
The incidences of aGVHD and cGVHD were also analyzed.
All nominal and continuous characteristics were described the usual
tables and indexes; comparisons were done using standard nonparametric
tests, including the chi-square or Fishers exact test for categorical variables
and the Mann-Whitney Utest for continuous variables. Survival curves were
estimated using the Kaplan-Meier method, with group comparison using the
log-rank test. Prognostic factors for OS after relapse were analyzed for statis-
tical significance using the Cox proportional hazards model. Factors that
showed a significance of P < .10 were included in a multivariate Cox regres-
sion model: age, number of lines before allo-HSCT, extramedullary disease at
allo-HSCT, extramedullary disease at relapse, aGVHD, and cGVHD. The proba-
bilities of disease progression and GVHD were calculated using cumulative
incidence estimates. NRM and RI were analyzed and compared using Gray’s
test. Cumulative incidence was computed with the cmprsk package for R ver-
sion 2.14.0 (R Institute for Statistical Computing, Vienna, Austria), and other
analyses were performed using SPSS 19.0 (IBM, Armonk, NY).
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Patient Characteristics, Conditioning Regimens, and GVHD
Prophylaxis
Baseline and transplantation characteristics of the 126
patients with MM who underwent allo-HSCT between January
2000 and December 2013 are summarized in Table 1. The
median duration of follow-up for surviving patients wasTable 1
Baseline Patient and Transplantation Characteristics (N = 126)
Characteristic Value
Age, yr, median (range) 52 (22-66)
Male sex, n (%) 78 (62)
IgG/IgA/Bence Jones/nonsecretory,
n (%)
68 (54)/23 (18)/31 (25)/4 (3)
ISS I/II/III, n (%)* 20 (28)/26 (37)/25 (35)
High cytogenetic risk: (t(4;14), t
(14;16), or 17p del), n (%)y
19 (29)
Number of treatment lines before
allo-HSCT, median (range)
3 (1-9)
1, n (%) 33 (26.2)
2-3, n (%) 62 (49.2)
>3, n (%) 31 (24.6)
PIs, n (%) 71 (56)
IMiDs, n (%) 48 (38)
Previous ASCT, n (%) 105 (83)
Time between diagnosis and allo-
HSCT
30 (8-130)
Allo-HSCT indication, n (%)
First response 15 (12)
Sensitive relapse 66 (52.3)
Refractory disease 45 (35.7)
Disease status at allo-HSCT, n (%)z
CR 16 (13)
VGPR/PR 86 (68)
Stable/progressive disease 22 (19)



















Peripheral blood stem cell source 111 (89)
CD34+ cells infused per kg,£ 106,
median (range)
4.8 (.5-14.2)











ISS indicates Injury Severity Score; VGPR, very good partial response.
* ISS data available for 71 patients.
y Fluorescein in situ hybridization data available for 65 patients.
z Disease status at allo-HSCT available for 124 patients.92 months (range, 22 to 197 months). In the pretransplantion
period, 71 patients (56%) had been treated with a PI-containing
regimen and 48 (38%) had received an ImiD-containing regi-
men. Thirty-six patients (28.5%) received both agents. Details
of the PI- and ImiD-based regimens are provided in Table 2.
Engraftment, GVHD, and NRM
All 126 patients engrafted. The incidence of grade II-IV
aGVHD was 47% (grade III-IV, 22%) and the 3-year cumulative
incidence of cGVHD was 51% (moderate, 14%; severe, 12%).
NRM within the first 100 days post-transplantation was 13%,
whereas the global NRM at any time was 31.7%. More informa-
tion is provided in Table 3.
Overall Outcomes after Transplantation
The overall response rate (ORR) after allo-HSCT was 74%,
with 56% of patients achieving CR. At day +100 after transplan-
tation, 82 patients (84.5%) either remained stable or showed
improved disease status compared with their status at trans-
plantation, including 13 patients with progressive or stable
disease at transplantation. Seventy-five patients (59.5%)
relapsed after allo-HSCT, 57 of them with extramedullary
involvement, with a median time to relapse or progression of 8
months post-transplantation (range, 1 to 141 months). The
cumulative incidences of NRM and relapse after allo-HCT are
shown in Figure 1.
After a median follow-up of 92 months for surviving
patients (range, 22 to 197 months), 85 patients (67.4%) died,
44 due to relapse or progression and 40 due to NRM. PFS was
24% at 2 years and 18% at 5 years, with a median PFS of 7
months (Figure 2).
Remarkably, even among patients who relapsed after allo-
HSCT, time to relapse discriminates subgroups of patients with
very different outcomes: patients who relapse <6 months, 6 to
24 months, and >24 months after transplant have a median OS
of 11 months, 68 months and not reached, respectively
(P < .001). Moreover, 83% of patients who relapsed at 12
months after transplantation were still alive at 5 years after
allo-HSCT, with a median OS not reached.
Evaluation of New Drug Efficacy before and after Allo-HSCT in
All Patients
Seventy-one patients (56%) received threatment with PIs in
the pretransplantation period, and 35 (27.7%) did so in the
post-transplantation period. The ORR after treatment with a
PI-based scheme was superior in the pretransplantation period
than in the post-transplantation period (76% versus 65.7%;
P > .05), with a longer time to progression (TTP) (13 months
versus 7 months; P > .05), although these differences did not
reach statistical significance. However, an in-depth evaluation
(Table 2) shows that the PI-based schemes used in the pre-
transplantation period were more intensive than those used in
the post-transplantation period, including ASCT with or with-
out maintenance in 21% of patients (n = 15) and high-intensity
combination chemotherapy regimens (VDLPACE/VDTPACE) in
15% (n = 11), whereas the majority of patients treated with PIs
post-HSCT received PI in monotherapy with or without ste-
roids (n = 21; 60%). Comparing response to PIs including equiv-
alent schemes in terms of intensity (Table 2), the ORR to
bortezomib with or without steroids was higher in the pre-
transplantation period than in the post-transplantation period
(79% versus 62%; P > .05), but similar when mono/polychemo-
therapy was added (60% versus 63%; P> .05). In addition, 4 out
of 5 patients responded to bortezomib plus panobinostat, and
1 patient responded to carfilzomib in the post allo-HSCT.
Table 2
New Drugs before and after Allo-HSCT
Drug Pre-HSCT Post-HSCT
PIs (any regimen) N = 71 N = 35




TTR, mo, median (range) 3 (1-10) 4 (1-9)
TTP, mo, median (range) 13 (1-108) 7 (1-132)
Scheme responses, ORR, % (n/N)
Bortezomib § steroids 79 (19/24) 62 (13/21)
Bortezomib +mono/polychemotherapy § steroids 60 (9/15) 63.6 (7/11)
VDLPACE/VDTPACE 82 (9/11) -
Bortezomib combination + ASCT §maintenance 100 (15/15) -
IMiDs (any regimen) N = 48 N = 33




TTR, mo, median (range) 4 (2-8) 4 (1-14)
TTP, mo, median (range) 7 (2-31) 10.5 (1-38)
Scheme responses, ORR, % (n/N)
Thalidomide § steroids 80 (4/5) 80 (4/5)
Thalidomide +mono/polychemotherapy § steroids 72.7 (8/11) 77.7 (7/9)
Lenalidomide § steroids 91.6 (11/12) 72 (8/12)
Lenalidomide +mono/polychemotherapy § steroids — 75 (3/4)
VDLPACE/VDTPACE 82 (9/11) —
IMiD combination + ASCT §maintenance 100 (3/3) —
PI-IMiD combinations, ORR, % (n/N)
Bortezomib + IMiD § steroids 33.3 (1/3) 85.7 (6/7)
Thalidomide + bortezomib § steroids 0 (0/1) 100 (1/1)
Lenalidomide + bortezomib § steroids 100 (1/1) 80 (4/5)
Pomalidomide + bortezomib § steroids 100 (1/1) 100 (1/1)
Second-generation new drugs, ORR, % (n/N)
Bortezomib + panobinostat § steroids 0 (0/1) 80 (4/5)
Carflizomib § steroids — 100 (1/1)
Thalidomide + elotuzumab § steroids 0 (0/2) —
Lenalidomide + panobinostat § steroids — 100 (1/1)
Lenalidomide + elotuzumab § steroids — 100 (1/1)
Pomalidomide § steroids 100 (1/1) 100 (4/4)
TTR indicates time to response; VDLPACE, bortezomib + dexamethasone + lenalidomide + adriamycin + cyclophosphamide + etoposide; VDTPACE,
bortezomib + dexamethasone + thalidomide + adriamycin + cyclophosphamide + etoposide.
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plantation period, and 33 (26%) did so in the post-transplanta-
tion period. The ORR to IMiD-containing regimens was
comparable in the post-transplantation and pretransplantation
periods (75% versus 76%; P = .50), but again, the regimens used
in the pretransplantation period were more intensive than
those used in the post-transplantation period, including ASCT
with or without maintenance in 6.25% (n = 3) and high-inten-
sity combination chemotherapy regimens (VDTPACE/
VDLPACE) in 23% (n = 11) (Table 2). Comparing responses to
IMiDs within equivalent schemes (Table 2), response rates
were not significantly different for thalidomide combinations,
although the ORR to lenalidomide with or without steroids
was higher in the pretransplantation period compared with
the post-transplantation period (91% versus 72%; P > .05). Of
note, all 4 patients who received post-allo-HSCT pomalidomide
with or without steroids responded, as did the 2 patients who
received IMiDs plus elotuzumab or panobinostat. Interestingly,TTP was significantly superior (7 months versus 10.5 months;
P = .04) in patients who received IMiDs within the post-allo-HSCT
setting, despite the fact that the regimens were less intensive.
In addition, 3 patients received PI plus IMiD combina-
tion therapy in the pretransplantation period and 7 did
so in the post-transplantation period, with superior ORR in
the post-translpantation transplantation period (85.7% ver-
sus 66.6%; P > .05) (Table 2).
OS was 60% at 1 year after relapse and 53% at 2 years after
relapse, with a median OS after relapse of 33 months (range,
13 to 53 months) (Figure 3). In a multivariable model, the
absence of cGVHD was the most significant factor associated
with reduced OS after relapse (hazard ratio [HR], 3.48; 95%
confidence interval [CI], 1.6 to 7.1; P = .001). In addition, less
pretreated patients (ie, number of lines before allo-HSCT, 1
versus 2/3 versus 4) had better OS after relapse (HR, .41; 95%
CI, .08 to .68), just like absence of grade III-IV aGVHD had a
(HR, .29; 95% CI, 01-06; P < .01).
Table 3
Engraftment, GVHD, and NRM (N = 126)
Variable Value
Engraftment 126 (100)
Time to neutrophils >.5£ 109/L, d,
median (range)
16 (6-27)
Time to platelets >20£ 109/L, d,
median (range)
11 (0-18)
aGVHD, n (%) 68 (57)
Grade II-IV 59 (47)
Grade III-IV 28 (22)
cGVHD at 3 yr, n (%) 64 (51)
Mild, moderate, severe, unknown 11 (9)/13 (10)/11 (9)/29 (23)
NRM, n (%)
At day +100 17 (13)
Global 40 (31.8)
Causes of death, n (%)
GVHD 17 (42.5)




Pulmonary toxicity 1 (2.5)
Pulmonary hemorrhage 1 (2.5)
Sinusoidal obstruction syndrome 1 (2.5)
Other causes 3 (7.5)
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Patients Receiving the Same Drug before and after Allo-HSCT
To further compare drug sensitivity before and after allo-
HSCT, we next focused only on those patients receiving PIs
and/or IMiDs before allo-HSCT and the same drug after trans-
plantation and compared the responses in the same patient
before and after allo-HSCT. Eighteen out of 75 patients who



























Figure 1. Cumulative incidences of NRboth the pretransplantation and post-transplantation periods.
Fifteen of these 18 patients achieved at least a partial response
(PR) (CR, n = 6) before transplantation, and 11 of these 15
patients responded again when they received PIs after allo-
HSCT (CR, n = 3). Moreover, 2 of the 3 patients who were
refractory to PIs before allo-HSCT responded when PIs were
used as salvage therapy after HSCT. Finally, 5 patients who did
not respond to PIs in the post-transplantation period achieved
stable disease, with TTP between 4 and 8 months.
In contrast, 12 out of 75 patients who relapsed after allo-
HSCT received IMiDs in both the pretransplantation and post-
transplantation periods. Ten of these 12 patients achieved at
least PR pretransplantation (CR, n = 3) and, when they were
retreated post-allo-HSCT, 7 responded again to IMiDs (CR,
n = 2). Moreover, 2 patients who were refractory before allo-
HSCT responded to IMiDs post-transplantation. Finally, 2 of 3
patients who were refractory to IMiDs in the post-transplanta-
tion period achieved stable disease, with a TTP of 8 months in
one and 13 months in the other.
Remarkably, in the group of patients who responded to
either PIs or IMiDs in both the pretransplantation and post-
transplantation periods, the time to response and TTP were
equivalent, even though the regimens were significantly more
intensive in the pretransplantation period. Outcomes and
treatment responses of patients who received PIs and IMiDs in
both the pretransplantation and post-transplantation periods
are summarized in Table 4.
Toxicity of PIs and IMiDs after Allo-HSCT
Regarding salvage treatment toxicity, 14 of 33 patients
treated with IMiDs had a previous history of aGVHD, and 15 had
a previous history of cGVHD. GVHD reactivation was reported
in 2 patients, both of whom were treated with a lenalidomide-
based regimen. One patient with a previous history of aGVHD
and cGHVD developed late aGVHD after 3 cycles of lenalidomide
plus prednisone with skin involvement, and another patient
with a previous history of cGVHD developed a new episode of60 80 100 120
onths
M and relapse after allo-HSCT.
Figure 2. PFS and OS.
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after 2 cycles of lenalidomide plus prednisone. In contrast, 19 of
35 patients treated with PIs had a history of previous aGVHD,
and 17 had a history of previous cGVHD. No GVHD flares were
reported. In addition, 2 patients developed grade 2 liver toxicity,
and 4 patients developed grade 3-4 peripheral neuropathy; only
1 patient needed to discontinue bortezomib.
Hematologic toxicity was reported in 6 patients and was
related to low neutrophil and platelet counts (thrombocytopenia
and neutropenia in 4 patients and grade 2 thrombocytopenia in 2
patients.
DISCUSSION
Allo-HSCT is usually relegated to advanced lines of treat-
ment based on the assumption that once relapse has occurred
after transplantation, no other rescue therapy is appropriate
for these patients, due to either ineffectiveness or toxicity.
Nevertheless, the present study, as well as several previous
studies, have challenged this concept. Based on findings
reported by the EBMT [13], OS from the time of first relapse/
progression was superior in patients treated with ASCT/allo-
RIC compared with patients treated with ASCT alone (50%
versus 27% at 60 months; P = .003). The same finding was
recently reported by the Center of International Blood and
Marrow Transplant Research; although both cohorts (ASCT/
ASCT and ASCT/allo-HSCT) had a similar risk of death in the
first year after relapse (HR, .72; P= .12), the ASCT/allo-HSCT
group had superior OS (HR for death in ASCT/ASCT, 1.55;
P= .0052) beyond 12 months after relapse [28]. This observa-
tion might reflect the fact that allo-HSCT can modify the biol-
ogy of the disease, directly targeting the myelomatous
plasma cells as well as the microenvironment, and the well-
documented graft-versus-myeloma effect induced by reactive
allogeneic T cells may persist after relapse and contribute to
an enhanced disease response [29,30]. In line with this obser-
vation, our analysis showed that the presence of cGVHD was
the most important favorable factor predicting OS not onlyafter transplantation, but also after relapse. In this regard, the
immune profile of patients with MM has been characterized
in detail, and immune exhaustion, including such abnormali-
ties as a significant increment of TCR-gd+ T lymphocytes and
Tregs, altered distribution of BDCA-1+ myeloid dendritic cells
and tissue macrophages, and down-regulation of activation
markers in T lymphocytes, have been noted, all of which have
been correlated with a poorer outcomes outside of the trans-
plantation setting [31].
Accordingly, even after disease relapse, allo-HSCT might
represent an appropriate platform for the use of rescue treat-
ments based on novel drugs. Unfortunately, most of the recent
trials that have led to the approval of new drugs excluded allo-
HSCT recipients, and thus their efficacy has not been appropri-
ately evaluated in this setting. Moreover, neither the EBMT nor
the Center of International Blood and Marrow Transplant
Research retrospective study, in which the effects of new drugs
as salvage therapy after allo-HSCT were analyzed, compared
the efficacy of these drugs with that seen in the pretransplan-
tation setting. Thus, Coman et al [19] evaluated the efficacy of
lenalidomide with or without dexamethasone in 52 patients
who relapsed after allo-RIC and reported an ORR of 83%,
including 29% in CR. Of note, the development of GVHD was
associated with the response rate [19]. Similarly, Minnema et
al [20] administered lenalidomide with or without dexametha-
sone to 13 patients who relapsed after allo-HSCT. The ORR was
46% for lenalidomide alone and was increased to 87.5% with a
combination of lenalidomide and dexamethasone. Bensinger
et al [23] evaluated the response to and tolerability of lenalido-
mide monotherapy in 18 patients with MM who progressed or
relapsed after allo-HSCT. In their study, lenalidomide resulted
in extended disease control (>12 months) in 50% of patients.
Montefusco et al [21] reported a PFS of 31% and OS of 73%
using the combination of bortezomib/dexamethasone plus DLI
in patients with relapsed MM. El Cheikh et al [22] treated 37
patients with progressive or residual disease after allo-RIC
using bortezomib with (n = 26) or without (n = 11)
Figure 3. OS after relapse.
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18 months [22].
In our study, most patients responded to rescue therapies
including IMiDs (76%) and PIs (65.7%), in agreement with pub-
lished data. In addition, we had the opportunity to evaluate
the efficacy of different drug combinations used in the same
patient before and after allo-HSCT, representing a unique
opportunity to evaluate whether or not allo-HSCT modifies
drug sensitivity in relapsed patients and, to the best of our
knowledge, the first study to evaluate drug sensitivity to the
same drug in the same patient both before and after allo-HSCT.
Interestingly, we observed that efficacy, in terms of response
rate and duration of response, was at least similar to that
observed in the pretransplantation setting. Moreover, 4
patients who were refractory to PIs (n = 2) or IMiDs (n = 2)
before allo-HSCT responded when PIs or IMiDs were used
again as salvage therapy after allo-HSCT, and 7 of 9 patients
who did not respond to these agents after allo-HSCT achieved
stable disease, with TTP between 4 and 13 months.
In addition, information is scanty regarding the safety of
novel drugs used as rescue therapy after allo-HSCT. In this
regard, Coman et al [19] reported that 31% of patients
developed new or exacerbated aGVHD after lenalidomide
treatment as salvage therapy post-HSCT. In line with this
observation, Minnema et al [20] reported aGVHD in 5 out
of 13 patients who received lenalidomide as a single agent
after allo-HSCT, and Bensinger et al [23] reported that 2
out of 18 patients who received lenalidomide monotherapy
died due to GVHD. In our retrospective study, only 2 out of
the 24 patients treated with a lenalidomide-based regimen
developed GVHD. Dose, timing, and concomitant medica-
tions should be considered to explain these differences. On
the other hand, PIs seem to be safe for patients with MM
relapsing or progressing after allo-HSCT, without unex-
pected organ toxicities in a prospective phase II trial
reported by Monefusco et al [21], while El-Cheickh et al[22] reported no worsening of GVHD symptoms in patients
treated with bortezomib. In our series, none of the patients
who received PIs post-HSCT developed GVHD, and only 1
out of the 33 patients with MM discontinued bortezomib
treatment due to grade 3 neuropathy. Moreover, overall,
our study shows that both the hematologic and nonhema-
tologic toxicity profile observed with PIs and/or IMiDs post-
HSCT is not significantly different from that reported out-
side the allo-HSCT setting. The retrospective nature of the
present study should be emphasized to carefully consider
this toxicity profile, and prospective studies are needed to
confirm these data.
Although the role of allo-HSCT is controversial in MM, and
its use in the current era remains a topic of debate, it is worth
mentioning that even in this series of patients who relapsed
after allo-HSCT, long-term survival could be achieved. This was
especially true for patients who relapsed between 6 and 24
months after transplantation or at>24 months after transplan-
tation, in whom the median OS was 68 months and not
reached, respectively. Moreover, 83% of patients who relapsed
at 12 months after transplantation were still alive at 5 years
after allo-HSCT, with a median OS not reached. Thus, for very
high-risk patients, allo-HCT could be considered as a platform
for additional therapeutic strategies.
Our study is the first to compare the efficacy and toxicity of
novel drugs before and after allo-HSCT, and our findings show
that they can be used safely; moreover, the new immune sys-
tem may enhance the activity of these agents. Therefore,
patients with MM who relapse after allo-HSCT should be con-
sidered candidates for receipt of novel agents, which are safe
and allow for response rates in a similar proportion of patients
and with similar durability as in the pretransplantation period.
This pattern does not reproduce the usual course of the disease,
in which response rates and TTP decrease with consecutive lines
of treatment, suggesting that the new immune systemmay con-
tribute to the enhanced efficacy of novel drugs.
Table 4
Outcomes of Patients Treated with PIs and/or IMiDs in Both in the Pre- and Post-Allo-HSCT Settings (N = 23)
Pre-Allo-HSCT Post-Allo-HSCT
Patient PIs/IMiDs Response TTR, mo TTP, mo IPs/IMiDs Response TTR, mo TTP, mo Comments
Schemes (Line of Treatment) Schemes
1* Bz + polychemotherapy x 4 (2) PD - - Bz + Len + Pred x 10 (1) Stringent CR 6 60 No grade 3-4 toxicity. Severe cGVHD after DLI. Dead 5 yr after
relapseVDTPACE x 2 (4) PR7 2 -
2* Bz/CC x 6 + ASCT (1) VGPR 3 16 Thal x 8 (1°) VGPR 2 10 No grade 3-4 toxicity. Dead 4 yrs after relapse
Len + Dx x 9 (2) PR 4 11 Thal + CFM +Dx x 7 (2°) CR 4 12
Bz + LBH + Dx x 4 (3) SD - 6 Bz x 4 (3°) SD - 6
VDLPACE x 3 (5°) PR 3 - Bz + Poma + Pred x 6 (4°) SD - 8
3 Bz + Dx x 3 (2) SD - 2 Thal + CFM + Pred x 7 (1°) SD - 13 Grade 3 thrombocytopenia. Alive 44 months after relapse
PAD x 2 (3) SD - 2 Ben + Bz + Dx x 6 (2) PR 4 12
Len + Dx x 4 (4) PR 4 2
Thal + CFM +Dx x 8 (5) PR 5 -
4* Thal + Dx x 12 (1) CR 6 24 Bz x 7 (1) CR 6 10 No grade 3-4 toxicity. Dead 4 years after relapse
Bz + Dx x 5 (3) VGPR 4 - Len + Pred x 8 (2) PR 2 10
5* Thal/Dx x 5 + ASCT CR 7 16 Bz + Dx x 7 PR 3 7 No grade 3-4 toxicity. Alive 38 months after relapse
Bz/Dx x 6 + ASCT CR 4 6 Len + Dx x 8 PR 4 12
Len + Dx x 10 CR 9 - Len + CFM x 9 PR 6 11
Bz + Poma + Dx PR 9 -
6* Bz/Dx x 6 + ASCT (1) CR 3 24 Bz + Len + Dx x 11 (1) PR 7 - No grade 3-4 toxicity. Alive 54 months after relapse
7* Bz + Dx x 5 (2) CR 4 NA Bz + CFM x 6 (1) CR 3 7 No grade 3-4 toxicity. Alive 12 months after relapse
Len + Dx x 6 (2) PR 5 -
8* Bz + Dx x 6 (2) VGPR 3 NA Bz + Dx x 7 (1) PR 3 8 No grade 3-4 toxicity. Dead 3 years after relapse
Len + Dx x 11 (2) PR 6 12
9* Bz + CFM +Dx x 7 (2) PR 2 NA Bz x 6 (1) SD 6 Grade 3 thrombocytopenia. Dead 2.5 years after relapse
Thal x 6 (2) PR 2 4
Thal + CFM +Dx x 5 (3) PR 2 4
10* Bz + CFM +Dx x 4 (2) PR 2 NA Bz +Thal+Dx x 2 (3) SD - 4 Grade 3 thrombocytopenia. Dead 5 months after relapse
11* Bz/Dx x 6 + ASCT (1) CR 4 108 Len + Dx x 9 (2) PR 8 16 No grade 3-4 toxicity. Mild cGVHD after Len. Alive 28 months
after relapseBz + Dx x 7 (2) PR 4 - Bz + CFM x 8 (3) PR 3 7
12* Thal + CFM +Dx (2) PR 4 7 Bz (2) PR 4 7 No grade 3-4 toxicity. Poor performance status at relapse.
Died 1 year after relapseBz + Dx (3) CR 3 18
Len + Dx (4) PR 4 2
PAD (5) PR 3 -
13* Bz/Dx + ASCT (1) CR 3 18 Bz + chemo (1) PD - 2 No grade 3-4 toxicity. Very poor performance status at trans-
plant. Dead 4 months after transplantLen + Dx (2) PR 4 3
Bz + Len + Dx (4°) SD - 5
VDTPACE (5) PD - 1












Patient PIs/IMiDs Response TTR, mo TTP, mo IPs/IMiDs Response TTR, mo TTP, mo Comments
Schemes (Line of Treatment) Schemes
-
15* Bz + Dx x 4 (2) PR 5 - Bz (1) SD - 6 No grade 3-4 toxicity. Dead 144 months after relapse
Bz + LBH + Dx (3) SD - 4
Thal + CFM + Dx (4) SD - 4
Len + Dx (6) SD - 8
Thal + Elo + Dx (7) SD 4
16* Thal + CFM +Dx x 6 (2) CR 3 NA Bz x 7 (2) PR 3 8 No grade 3-4 toxicity. Dead 144 months after relapse
Bz + Dx x 2 (3) PD - 2 Thal + CFM + Pred x 11 (4) PR 4 9
17* VDTPACE x 2 (2) PR 2 - Thal + CFM x 2 (4) PD - - No grade 3-4 toxicity. Dead 5 months after relapse
18* Thal + CFM +Dx x 13 (4) PR 8 27 Len + Dx (2) PR 3 18 Mild GVHD reactivation with Len. Alive 36 months after
relapseLen + Dx x 3 (5) PD - -
VDTPACE x 2 (6) PR 2 -
19* Thal + polychemo (2) PR 2 6 Len + Dx (2) SD - 8 No grade 3-4 toxicity. Dead 12 months after relapse
20* Len + Dx x 6 (2) VGPR 3 - Len + LBH +Dx x 9 (2) VGPR 6 10 Grade 3 astenia. Alive 65 months after relapse
21* Bz + Len + Dx x 2 (2) SD - 2 Poma + Dx x 9 (3) PR 6 12
Thal + Elo + Dx x 3 (3) PD - 4 No grade 3-4 toxicity. Dead 15 months after relapse
VDLPACE x 3 (4) PR 2 -
22* Bz/Dx x 6+ ASCT (1) PR NA 8 Len + Carfilz + Dx x 3 (1) SD NA 4 No grade 3-4 toxicity. Alive 54 months after transplant
Len + Dx (2) PR NA - Poma + Dx x 8 (2) PR 3 8
23* Bz/Dx + ASCT (1) CR 4 30 Bz x 1 (1) - - - Poor performance status at transplantation. Dead after 1
month of monotherapy with BzThal + CFM +Dx (2) PR 4 -
Bz indicates bortezomib; PD, progressive disease; Len, lenalidomide; Pred, prednisone; Dx, dexamethasone; LBH, panobinostat; SD, stable disease; Thal, thalidomide; Elo, elotuzumab; CFM, cyclophosphamide; Poma, pomalidomide; PAD,
bortezomib + adryamicin + dexamethasone; Ben, bendamustine; NA, not available; Mel, melphalan; Carfilz, carfilzomib;
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